
Prices of coronary stents set to rise
The Hindu
NPPA allows price hike for coronary stents to reflect inflation, impacting heart patients' treatment costs in India.
The National Pharmaceutical Pricing Authority (NPPA) has allowed manufacturers and importers to increase the prices of coronary stents to reflect the rise in inflation.
In an order dated March 27, the NPPA directed all manufacturers and importers of coronary stents, whose retail prices are lower than the ceiling set by it, to review and revise the prices by 1.74028 per cent of the wholesale price index (WPI) for 2024. The move will result in a hike in treatment cost for heart patients.
With this, the ceiling price of bare metal stents will be revised to ₹10,692.69 per unit, while that of drug-eluting, biometallic and bioresorbable vascular scaffold (BVS) stents will be fixed at ₹38,933.14 per unit.
The order adds that the manufacturers not complying with the ceiling price would be liable to deposit the overcharged amount along with interest under the provisions of the Drugs Prices Control Order, 2013.
The NPPA instructed all retailers and dealers to display the price list furnished by the manufacturer at their business locations.
India faces a significant cardiac burden, with cardiovascular diseases being a leading cause of mortality and disability in 2024, driven by factors such as urbanisation, lifestyle changes, and rising rates of hypertension and obesity.